Durvalumab vs Lithium Carbonate

Durvalumab vs Lithium Carbonate: Overview

This comparison examines the pharmacological differences between Durvalumab and Lithium Carbonate.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Lithium Carbonate: Modulates intracellular signaling via inositol and GSK-3 inhibition.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Lithium Carbonate — 18-36 hours.

Chemical Properties

Molecular Formula: Lithium Carbonate — Li2CO3.

Molecular Weight: Lithium Carbonate — 73.8910 g/mol.

Type: Durvalumab — Antibody; Lithium Carbonate — Small molecule.